Neovasc Announces Participation in Noble Capital Markets Virtual Road Show Series
via NewMediaWire -- Neovasc, Inc. ("Neovasc" or the "Company")
(NASDAQ, TSX: NVCN), today announced their participation in
Noble Capital Markets’ Virtual Road Show Series, presented by
Channelchek, scheduled for December 8, 2020.
The virtual road show will feature a corporate presentation from
Neovasc President & CEO, Fred Colen, followed by a Q & A
session proctored by Noble Biotechnology Research Analyst Ahu
Demir, Ph.D., featuring questions submitted by the audience.
The live broadcast of the virtual road show is
scheduled for December 8, 2020, at 1 PM EST. Registration is
free, but limited to 100. Register Here.
About Neovasc Inc.
Neovasc is a specialty medical device company that
develops, manufactures and markets products for the rapidly growing
cardiovascular marketplace. Its products include Reducer, for the
treatment of refractory angina, which is not currently commercially
available in the United States and has been commercially available
in Europe since 2015, and Tiara, for the transcatheter treatment of
mitral valve disease, which is currently under clinical
investigation in the United States, Canada, Israel and Europe. For
more information, visit: www.neovasc.com.
About Noble Capital Markets
Noble Capital Markets, Inc. was incorporated in
1984 as a full-service SEC / FINRA registered broker-dealer,
dedicated exclusively to serving underfollowed small / microcap
companies through investment banking, wealth management, trading
& execution, and equity research activities. Over the past 36
years, Noble has raised billions of dollars for these companies and
published more than 45,000 equity research reports.
www.noblecapitalmarkets.com email: firstname.lastname@example.org
Channelchek (.com) is a comprehensive
investor-centric portal - featuring more than 6,000 emerging growth
companies - that provides advanced market data, independent
research, balanced news, video webcasts, exclusive c-suite
interviews, and access to virtual road shows. The site is available
to the public at every level without cost or obligation. Research
on Channelchek is provided by Noble Capital Markets, Inc., an SEC /
FINRA registered broker-dealer since
1984. www.channelchek.com email: email@example.com
Forward-Looking Statement Disclaimer
Certain statements in this news release contain
forward-looking statements within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and applicable Canadian
securities laws that may not be based on historical fact.
When used herein, the words "expect", "anticipate", "estimate",
"may", "will", "should", "intend," "believe", and similar
expressions, are intended to identify forward-looking statements.
Forward-looking statements may involve, but are not limited to, the
expected impact on Reducer revenue generation during the fourth
quarter, the Company’s ability to build on progress and optimizing
the value of its devices, the likelihood of approval under the
FDA’s decision on the PMA, the expansion of its product range,
prospects for regulatory approvals and the growing cardiovascular
marketplace. Forward-looking statements are based on estimates and
assumptions made by the Company in light of its experience and its
perception of historical trends, current conditions and expected
future developments, as well as other factors that the Company
believes are appropriate in the circumstances. Many factors could
cause the Company's actual results, performance or achievements to
differ materially from those expressed or implied by the
forward-looking statements, including those described in the "Risk
Factors" section of the Company's Annual Report on Form 20-F and in
the Management's Discussion and Analysis for the three and nine
months ended September 30, 2020 (copies of which may be obtained
at www.sedar.com or www.sec.gov). These factors
should be considered carefully, and readers should not place undue
reliance on the Company's forward-looking statements. The Company
has no intention and undertakes no obligation to update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.